Doxorubicin – Medxy AI

Anthracycline Cardiotoxicity Exacerbated by Metabolic Stress in Pressure-Overloaded Hearts: Mechanistic Insights and Clinical Implications

By MedXY 09/21/2026

Left ventricular pressure overload induces metabolic vulnerability that heightens susceptibility to anthracycline cardiotoxicity, revealing a critical need for targeted preventive strategies in patients with hypertension or valvular disease undergoing chemotherapy.

news Oncology Specialties

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY 08/13/2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safety profiles.

Clinical Updates Family Medicine & Nutrition news Oncology Specialties

Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity

By MedXY 08/06/2025

This review explores vitamin C's potential to protect the heart from doxorubicin-induced damage by reducing oxidative stress and preserving cardiac function, highlighting the need for further clinical studies.